Telix-ITM merger aims to create radiopharma juggernaut: Deals Report

Telix Pharmaceuticals is acquiring German radiopharma company ITM Isotope Technologies Munich in an all-stock deal valuing ITM at $1.65 billion on a cash- and debt-free basis. ITM shareholders will receive about $1.25 billion in Telix shares and are eligible for $700 million in additional payouts. The combined company gains global scale, manufacturing capabilities and an oncology product that could soon reach the market.